Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro

British Journal of Clinical Pharmacology

Volumn 57, Issue 3, 2004, Pages 349-353

  Granfors, Marika T ^a   Backman, Janne T ^a   Laitila, Jouko ^a   Neuvonen, Pertti J ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

CYP1A2; Elimination; in vitro; Tizanidine

Indexed keywords

CYTOCHROME P450 1A2; FLUVOXAMINE; FURAFYLLINE; TIZANIDINE;

ARTICLE; CATALYSIS; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; LIVER CLEARANCE; LIVER MICROSOME; PREDICTION; PRIORITY JOURNAL;

CLONIDINE; CYTOCHROME P-450 CYP1A2; HALF-LIFE; HUMANS; MICROSOMES, LIVER;

EID: 1542329740     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.02028.x     Document Type: Article

References (23)

1. Wagstaff AJ, Bryson HM. Tizanidine: A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs 1997; 53: 435-52.
2. Lake AE III, Saper JR. Chronic headache. New advances in treatment strategies. Neurology 2002; 59(Suppl 2): S8-S13.
3. Koch P, Hirst DR, von Wartburg BR. Biological fate of sirdalud in animals and man. Xenobiotica 1989; 19: 1255-65.
4. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993; 45: 1211-14.
5. Eagling VA, Tjia JF, Back DJ. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br J Clin Pharmacol 1998; 45: 107-14.
6. Fuhr U, Anders E-M, Mahr G, Sörgel F, Staib AH. Inhibitory potency of quinolone antibacterial agents against cytochrome P4501A2 activity in vivo and in vitro. Antimicrob Agents Chemother 1992; 36: 942-8.
7. Ko J-W, Sukhova N, Thacker D, Chen P, Flockhart DA. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 1997; 25: 853-62.
8. Newton DJ, Wang RW, Lu AYH. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 1995; 23: 154-8.
9. Wen X, Wang J-S, Backman JT, Laitila J, Neuvonen PJ. Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug Metab Dispos 2002; 30: 631-5.
10. Lee J, Seo JH, Kim D-H. Determination of tizanidine in human plasma by gas chromatography-mass spectrometry. Analyst 2002; 127: 917-20.
11. Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, Sugiyama Y. Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos 2001; 29: 1316-24.
12. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1093-5.
13. Iwatsubo T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, Yokoi T, Kamataki T, Sugiyama Y. Prediction of in vivo hepatic metabolic clearance of YM796 from in vitro data by use of human liver microsomes and recombinant P-450 isozymes. J Pharmacol Exp Ther 1997; 282: 909-19.
14. Wilkinson GR. Clearance approaches in pharmacology. Pharmacol Rev 1987; 39: 1-47.
15. Lin JH, Lu AYH. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 1997; 49: 403-49.
16. Bunch C, DRUGDEX® editorial staff. Tizanidine. In DRUGDEX® Systems MICROMEDEX, eds Hutchison TA, Shahan DR. Greenwood Village, Colorado, Vol. 117 expires 09/2003.
17. Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab 2002; 3: 13-37.
18. Wang J-S, Backman JT, Taavitsainen P, Neuvonen PJ, Kivistö KT. Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans. Drug Metab Dispos 2000; 28: 959-65.
19. Bargetzi MJ, Aoyama T, Gonzalez FJ, Meyer UA. Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4. Clin Pharmacol Ther 1989; 46: 521-7.
20. Imaoka S, Enomoto K, Oda Y, Asada A, Fujimori M, Shimada T, Fujita S, Guengerich FP, Funae Y. Lidocaine metabolism by human cytochrome P-450s purified from hepatic microsomes: Comparison of those with rat hepatic cytochrome P-450s. J Pharmacol Exp Ther 1990; 255: 1385-91.
21. Isohanni MH, Neuvonen PJ, Olkkola KT. Effect of erythromycin and itraconazole on the pharmacokinetics of oral lignocaine. Pharmacol Toxicol 1999; 84: 143-6.
22. Isohanni MH, Neuvonen PJ, Palkama VJ, Olkkola KT. Effect of erythromycin and itraconazole on the pharmacokinetics of intravenous lignocaine. Eur J Clin Pharmacol 1998; 54: 561-5.
23. Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivistö KT. Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. Clin Pharmacol Ther 2001; 69: 194-200.